These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 4701137)

  • 21. [Antituberculosis chemotherapy including ofloxacin in patients with pulmonary tuberculosis not treated previously].
    Tsukamura M; Yoshii S; Yasuda Y; Saito H
    Kekkaku; 1986 Jan; 61(1):15-7. PubMed ID: 3458966
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ambulatory and hospitalintermittent intravenous chemotherapy of pulmonary tuberculosis in a rural district].
    Ursov IG; Volokitin FN; Kononenko VG
    Sov Med; 1979 Apr; (4):108-10. PubMed ID: 375418
    [No Abstract]   [Full Text] [Related]  

  • 23. [Actual tuberculosis therapy. An attempt to simplify and to determine a schedule of tuberculosis chemotherapy].
    Virchow C
    Munch Med Wochenschr; 1969 Aug; 111(35):1717-22. PubMed ID: 4309162
    [No Abstract]   [Full Text] [Related]  

  • 24. [Urgent problems of antibacterial treatment of pulmonary tuberculosis].
    Pilipchuk NS
    Vrach Delo; 1981 Jan; (1):47-9. PubMed ID: 7010782
    [No Abstract]   [Full Text] [Related]  

  • 25. [A controlled comparison of daily and intermittent triple drug regimens (SM-INH-EB) in original treatment. Report of the 16th series of Controlled Trial of Chemotherapy (author's transl)].
    Kekkaku; 1974 Aug; 49(8):247-52. PubMed ID: 4427402
    [No Abstract]   [Full Text] [Related]  

  • 26. [Supervision in the chemotherapy of tuberculosis].
    Bignall JR
    Plucne Bolesti Tuberk; 1970; 22(4):310-4. PubMed ID: 5208398
    [No Abstract]   [Full Text] [Related]  

  • 27. Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. II. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with SM- and INH-resistant Schacht strain.
    Hokama S
    Jpn J Tuberc; 1967 Jul; 14(1):45-54. PubMed ID: 4295381
    [No Abstract]   [Full Text] [Related]  

  • 28. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 29. [Has the intermittent therapy of pulmonary tuberculosis a future in industrialised countries?].
    Gyselen A; Verbist L
    Prax Pneumol; 1972 May; 26(5):269-82. PubMed ID: 5047988
    [No Abstract]   [Full Text] [Related]  

  • 30. [The adverse effects of 2 therapy combinations (SM, PAS, INH, RMP, INH, EMB) in the intensive treatment phase of pulmonary tuberculosis].
    Knop P; Kindler U; Merholz T
    Med Welt; 1976 Feb; 27(8):389-90. PubMed ID: 1256308
    [No Abstract]   [Full Text] [Related]  

  • 31. Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months.
    Trébucq A; Rieder HL
    Int J Tuberc Lung Dis; 1998 Mar; 2(3):184-6. PubMed ID: 9526189
    [No Abstract]   [Full Text] [Related]  

  • 32. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
    Shah AR; Agarwal SK; Shah KV
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ways of increasing chemotherapy effectiveness in pulmonary tuberculosis].
    Ershov AI; Tikhonov VA; Grigaliunas AP; Sushkin AG; Guzeeva SA
    Vrach Delo; 1981 May; (5):21-5. PubMed ID: 7257254
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of lymphotropic therapy in the multimodality treatment of patients with pulmonary tuberculosis and comorbidity].
    Ubaĭdullaev AM; Belotserkovets VG
    Probl Tuberk Bolezn Legk; 2004; (12):50-2. PubMed ID: 15719669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

  • 37. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):10-5. PubMed ID: 9562106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [[Comparative studies on therapeutic effects of SM.INH.PAS, SM.INH.PAS.EB twice weekly, and SM.INH.PAS.EB daily in original treatment cases of pulmonary tuberculosis].
    Kekkaku; 1971 Aug; 46(8):325-33. PubMed ID: 4998863
    [No Abstract]   [Full Text] [Related]  

  • 39. [Duration of the treatment of tuberculosis in 1981].
    Sors C; Dautzenberg B; Grosset J
    Nouv Presse Med; 1982 Mar; 11(11):831. PubMed ID: 7070974
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment modalities applied to tuberculosis patients in a French department. Hautes-Pyrénées, 1973 to 1980].
    Hetrick G; Humarau H
    Rev Fr Mal Respir; 1983; 11(6):883-7. PubMed ID: 6669799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.